(p)ppGpp/GTP and Malonyl-CoA Modulate Staphylococcus aureus Adaptation to FASII Antibiotics and Provide a Basis for Synergistic Bi-Therapy-Reference-Cited by-同舟云学术

(p)ppGpp/GTP and Malonyl-CoA Modulate Staphylococcus aureus Adaptation to FASII Antibiotics and Provide a Basis for Synergistic Bi-Therapy

Published:2021-02-23 Issue:1 Volume:12 Page:
ISSN:2150-7511
Container-title:mBio
language:en
Short-container-title:mBio

Author:

Pathania Amit¹,Anba-Mondoloni Jamila¹,Gominet Myriam²,Halpern David¹,Dairou Julien³,Dupont Laëtitia¹,Lamberet Gilles¹,Trieu-Cuot Patrick²,Gloux Karine¹,Gruss Alexandra¹

Affiliation:

1. Micalis Institute, INRAE, AgroParisTech, Université Paris-Saclay, Jouy en Josas, France

2. Unité de Biologie des Pathogènes à Gram-positif, CNRS UMR 2001, Institut Pasteur, Paris, France

3. Université de Paris, CNRS UMR8601, Paris, France

Abstract

Staphylococcus aureus is a major human bacterial pathogen for which new inhibitors are urgently needed. Antibiotic development has centered on the fatty acid synthesis (FASII) pathway, which provides the building blocks for bacterial membrane phospholipids.

Funder

DIM Malinf (Domaine d'Intérêt Majeur, Maladies Infectieuses) from the Conseil Régional d'Ile-de-France

Agence Nationale de la Recherche

Fondation pour la Recherche Médicale

French Government Investissement d'Avenir program, Laboratoire d'Excellence Integrative Biology of Emerging Infectious Diseases

Publisher

American Society for Microbiology

Subject

Virology,Microbiology

Link

https://journals.asm.org/doi/pdf/10.1128/mBio.03193-20

Reference50 articles.